EQT has divested Fertin Pharma to Philip Morris International for DKK 5.1 billion, aligning both companies towards a smoke-free future and innovative healthcare solutions.
Target Information
Fertin Pharma is a prominent contract development and manufacturing organization (CDMO) specializing in innovative oral and intra-oral delivery technologies. The company's advanced solutions empower individuals globally to lead healthier lives, particularly through products that assist consumers in reducing and ultimately quitting tobacco use. In 2020, Fertin successfully manufactured nearly three billion doses of nicotine replacement therapy (NRT) products, showcasing its significant impact on public health.
In 2017, EQT acquired a 70% stake in Fertin from the Bagger-Sørensen family. During its ownership period, EQT has guided Fertin through a strategic transformation, shifting its focus from NRT specialization to becoming a leader in oral and intra-oral drug delivery technologies. This transition was supported by substantial investments in manufacturing capabilities and development initiatives, enabling Fertin to serve a diverse and expanding clientele, including some of the largest pharmaceutical and healthcare companies worldwide.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The pharmaceutical and healthcare industries are undergoing dynamic changes, particularly in the realm of drug delivery technologies. As global health concerns rise, the demand for innovative solutions that enhance therapeutic efficacy a
Similar Deals
Philip Morris International
invested in
Fertin Pharma
in 2023
in a Other deal
Disclosed details
Transaction Size: $757M
Enterprise Value: $757M